Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the remicade biosimilar market grown in recent years?
The market size for the remicade biosimilar has seen substantial growth in recent times, expanding from $3.95 billion in 2024 to an estimated $4.93 billion in 2025, indicating a compound annual growth rate (CAGR) of 24.9%. The significant growth during the historical period can be linked to factors such as the launch of remicade (infliximab), advancements in biotechnology, the expiration of biologics patents, the establishment of a regulatory pathway, and pressures in healthcare costs.
How is the remicade biosimilar market size expected to evolve during the forecast period?
Over the next few years, the remicade biosimilar market is projected to witness remarkable growth. By 2029, it would attain a value of $11.07 billion, escalating at a Compound Annual Growth Rate (CAGR) of 22.4%. The swift growth during the forecast period can be accredited to the expiration of patents, an increase in demand for affordable treatments, the development of biosimilar pipelines, the consolidation of the market, and reimbursement policies. Noteworthy trends to watch for within this period comprise changes in doctor prescription habits, the management of the biosimilar life cycle, naming conventions for biosimilars, interchangeability of biosimilars, and evidence from the real world regarding biosimilars.
Get your remicade biosimilar market report here!
https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report
Which key drivers are propelling the remicade biosimilar market’s growth?
The escalation in the prevalence of autoimmune diseases is anticipated to drive the expansion of the remicade biosimilar market. Autoimmune diseases constitute disorders where the immune system erroneously harms the body’s tissues and organs. Remicade biosimilars offer an efficient therapeutic solution for alleviating symptoms and curbing inflammation linked to these conditions. For example, in July 2023, Public Health Scotland, a Scottish organization, revealed that in 2022 the percentage of newly diagnosed patients suffering from multiple sclerosis (MS) leaped to 87.2%, an increase from 85.7% in 2020. A total of 491 fresh cases were documented, accumulating the total figure to 6,359 in 2022. Thus, the escalating prevalence of autoimmune diseases is fuelling the expansion of the remicade biosimilar market.
What are the market segments in the remicade biosimilar industry?
The remicade biosimilar market covered in this report is segmented –
1) By Type: 100mg/10ml, 500mg/50ml
2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis
3) By Application: Blood Disorders, Oncology Diseases
Subsegments:
1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes
2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp
Which leading companies are shaping the growth of the remicade biosimilar market?
Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A
What key trends are currently impacting the remicade biosimilar market’s development?
Product innovation is emerging as a significant trend in the Remicade biosimilar market. Big players in the Remicade biosimilar market are creating inventive products to maintain their standing. For instance, in January 2023, U.S.-based biotechnology firm Amgen Inc. rolled out Amjevita, a biosimilar equivalent of AbbVie’s Humira, in the U.S, engineered to be as secure and effective as the authentic drug. Amjevita, being Humira’s first biosimilar, is set to vie with Humira for market share. This biological medicine treats various autoimmune illnesses, including rheumatoid arthritis and Crohn’s disease. It ranks among the highest-priced drugs globally, contributing billions in annual sales for AbbVie. Nonetheless, Amjevita’s cost is expected to be significantly lower, offering monetary savings and increased treatment options for patients.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11952
Which geographic areas are influencing the growth of the remicade biosimilar market?
Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Biologics Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery
https://www.thebusinessresearchcompany.com/report/biologics-market
Pharmaceutical API Manufacturing Global Market Report 2024
Agricultural Biologics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/agricultural-biologics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
